ISA Pharmaceuticals to present at the ASCO Annual Meeting 2024
April 16, 2024
• An abstract detailing results from a randomized, placebo-controlled trial in advanced head and neck cancer, was accepted for oral presentation
• Results provide key insights for the clinical application of cancer vaccines
Oegstgeest, The Netherlands, 16 April 2024 – ISA Pharmaceuticals B.V., a clinical-stage biopharmaceutical company developing immunotherapies to treat cancers and serious infectious diseases, today announced acceptance of its ISA101b study abstract as an oral presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual meeting. This abstract describes results of a randomized trial in advanced head and neck cancer with its lead therapeutic vaccine ISA101b. These results provide key insights in the clinical application of cancer vaccines.
ISA101b is a cancer vaccine that targets human papillomavirus type 16 (HPV16) positive cancers. It induces strong and specific T-cell immune responses to the HPV16 virus, and (re-)establishes a powerful and targeted T-cell immune response against infected and/or cancerous cells and tissues. ISA Pharmaceuticals sees a clear path forward and is looking to partner ISA101b for Phase 3 clinical development.
Head-and-neck cancer can be a severe and life-threatening disease. HPV16 is a major cause of head-and-neck cancer. Recurrent and metastatic HPV16 positive OPC is a form of head-and-neck cancer with a high unmet medical need. In September 2021 ISA101b was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of recurrent and metastatic HPV16 positive OPC.
For more information, please contact us at info@isa-pharma.com or visit us at isa-pharma.com.
-Ends-
For more information contact:
ISA Pharmaceuticals
Business Development
Anton Mat
Tel: +3185 8229292
About ISA Pharmaceuticals
ISA Pharmaceuticals is an immunotherapy company developing treatments for various cancers and infectious diseases. ISA has best-in-class technology to stimulate and activate the human immune system, specifically T cells, to fight diseased or infected cells. Its lead asset ISA101b has finished phase 2 clinical trials for human papillomavirus type 16 (HPV16)-induced cancers, and is ready for Phase 3 clinical development. Other pipeline assets include ISA104, a clinical stage immunotherapy to treat patients that suffer from chronic hepatitis B infection, and ISA103, a preclinical stage anti-PRAME cancer vaccine. For more information, please visit www.isa-pharma.com.
About ISA101b
ISA101b immunotherapy targets human papillomavirus type 16 (HPV16) positive cancers. It induces strong and specific T-cell immune responses to the HPV16 virus, and (re-)establishes a powerful and targeted T-cell immune response against infected and/or cancerous cells and tissues. ISA101b is using ISA’s proprietary Synthetic Long Peptide (SLP®) technology. In September 2021 ISA101b was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of recurrent and metastatic HPV16 positive oropharyngeal cancer (OPC). ISA101b is ready for Phase 3 clinical development.
